Dyax Corp. Creates COO Position and Expands Executive Roles
Ivana Magovcevic-Liebisch, Ph.D., J.D., Named Chief Operating Officer
Dyax Corp. announced the appointment of Ivana Magovcevic-Liebisch, Ph.D., J.D., to the new position of Executive Vice President, Chief Operating Officer, and the appointment of Burt Adelman, M.D., Chief Medical Officer, to Executive Vice President.
In the COO role, Dr. Magovcevic-Liebisch will be responsible for the execution of corporate strategy and achievement of corporate goals related to the Company's commercial operations, research, legal and business development departments, among others under her supervision. Dr. Adelman will assume similar responsibilities for the clinical/medical affairs and regulatory departments, in addition to technical operations, which includes manufacturing, quality assurance and quality control.
Dr. Magovcevic-Liebisch joined Dyax in April 2001, and has served as an executive officer at the Company since 2005. During her tenure, Dr. Magovcevic-Liebisch has been appointed to roles of increasing responsibility. She has served as Vice President of Intellectual Property, Executive Vice President and General Counsel, and, most recently, Executive Vice President and Chief Business Officer.
Dr. Adelman joined Dyax in February 2012. Prior to joining Dyax, Dr. Adelman was interim President of Research and Development at Eleven Biotherapeutics. Dr. Adelman previously served as the Executive Vice President, Portfolio Strategy, at Biogen Idec, where he also held the positions of Executive Vice President, Development, and Executive Vice President, Research and Development.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
